These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 28700961

  • 21. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D.
    Dalton Trans; 2016 Nov 01; 45(43):17233-17240. PubMed ID: 27722707
    [Abstract] [Full Text] [Related]

  • 22. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
    Lee KGZ, Babak MV, Weiss A, Dyson PJ, Nowak-Sliwinska P, Montagner D, Ang WH.
    ChemMedChem; 2018 Jun 20; 13(12):1210-1217. PubMed ID: 29637702
    [Abstract] [Full Text] [Related]

  • 23. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H, Yan L, Zhang Y, Qi R, Li W, Wang R, Liu S, Huang Y, Li Y, Jing X.
    Chem Commun (Camb); 2012 Nov 11; 48(87):10730-2. PubMed ID: 23012698
    [Abstract] [Full Text] [Related]

  • 24. Overcoming tumor resistance to cisplatin by cationic lipid-assisted prodrug nanoparticles.
    Cao ZT, Chen ZY, Sun CY, Li HJ, Wang HX, Cheng QQ, Zuo ZQ, Wang JL, Liu YZ, Wang YC, Wang J.
    Biomaterials; 2016 Jul 11; 94():9-19. PubMed ID: 27088406
    [Abstract] [Full Text] [Related]

  • 25. ctc-[Pt(NH3)2(cinnamate)(valproate)Cl2] is a highly potent and low-toxic triple action anticancer prodrug.
    Li Y, Shi S, Zhang S, Gan Z, Wang X, Zhao X, Zhu Y, Cao M, Wang X, Li W.
    Dalton Trans; 2021 Aug 28; 50(32):11180-11188. PubMed ID: 34338267
    [Abstract] [Full Text] [Related]

  • 26. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
    Dai Y, Zhu Y, Cheng J, Shen J, Huang H, Liu M, Chen Z, Liu Y.
    Chem Commun (Camb); 2020 Nov 12; 56(90):14051-14054. PubMed ID: 33103676
    [Abstract] [Full Text] [Related]

  • 27. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
    Jin S, Guo Y, Song D, Zhu Z, Zhang Z, Sun Y, Yang T, Guo Z, Wang X.
    Inorg Chem; 2019 May 06; 58(9):6507-6516. PubMed ID: 31013065
    [Abstract] [Full Text] [Related]

  • 28. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R, Wang Y, Yan L, Ma L, Wang Z, Chan HC, Chiu SK, Chen X, Zhu G.
    Chem Commun (Camb); 2015 May 07; 51(37):7859-62. PubMed ID: 25854514
    [Abstract] [Full Text] [Related]

  • 29. Multiaction Pt(IV) Prodrugs Releasing Cisplatin and Dasatinib Are Potent Anticancer and Anti-Invasive Agents Displaying Synergism between the Two Drugs.
    Markova L, Maji M, Kostrhunova H, Novohradsky V, Kasparkova J, Gibson D, Brabec V.
    J Med Chem; 2024 Jun 13; 67(11):9745-9758. PubMed ID: 38819023
    [Abstract] [Full Text] [Related]

  • 30. The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions.
    Gabano E, Ravera M, Trivero F, Tinello S, Gallina A, Zanellato I, Gariboldi MB, Monti E, Osella D.
    Dalton Trans; 2018 Jun 25; 47(25):8268-8282. PubMed ID: 29892758
    [Abstract] [Full Text] [Related]

  • 31. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
    Ravera M, Perin E, Gabano E, Zanellato I, Panzarasa G, Sparnacci K, Laus M, Osella D.
    J Inorg Biochem; 2015 Oct 25; 151():132-42. PubMed ID: 26277416
    [Abstract] [Full Text] [Related]

  • 32. Biotinylated Pt(IV) prodrugs with elevated lipophilicity and cytotoxicity.
    Spector D, Erofeev A, Gorelkin P, Skvortsov D, Trigub A, Markova A, Nikitina V, Ul'yanovskiy N, Shtil' A, Semkina A, Vlasova K, Zyk N, Majouga A, Beloglazkina E, Krasnovskaya O.
    Dalton Trans; 2023 Jan 24; 52(4):866-871. PubMed ID: 36629146
    [Abstract] [Full Text] [Related]

  • 33. An Anticancer PtIV Prodrug That Acts by Mechanisms Involving DNA Damage and Different Epigenetic Effects.
    Kostrhunova H, Petruzzella E, Gibson D, Kasparkova J, Brabec V.
    Chemistry; 2019 Apr 05; 25(20):5235-5245. PubMed ID: 30740808
    [Abstract] [Full Text] [Related]

  • 34. Biotinylated platinum(IV) complexes designed to target cancer cells.
    Zhao J, Hua W, Xu G, Gou S.
    J Inorg Biochem; 2017 Nov 05; 176():175-180. PubMed ID: 28917640
    [Abstract] [Full Text] [Related]

  • 35. A platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics for drug activation monitoring and combinatorial photodynamic-chemotherapy against cisplatin resistant cancer cells.
    Yuan Y, Zhang CJ, Liu B.
    Chem Commun (Camb); 2015 May 21; 51(41):8626-9. PubMed ID: 25898264
    [Abstract] [Full Text] [Related]

  • 36. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
    Qin X, Fang L, Chen F, Gou S.
    Eur J Med Chem; 2017 Sep 08; 137():167-175. PubMed ID: 28586717
    [Abstract] [Full Text] [Related]

  • 37. New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo.
    Song XQ, Ma ZY, Wu YG, Dai ML, Wang DB, Xu JY, Liu Y.
    Eur J Med Chem; 2019 Apr 01; 167():377-387. PubMed ID: 30784875
    [Abstract] [Full Text] [Related]

  • 38. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
    Shi H, Cheng Q, Yuan S, Ding X, Liu Y.
    Chemistry; 2015 Nov 09; 21(46):16547-54. PubMed ID: 26405808
    [Abstract] [Full Text] [Related]

  • 39. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
    Chen F, Pei S, Wang X, Zhu Q, Gou S.
    Biochem Biophys Res Commun; 2020 Jan 15; 521(3):753-761. PubMed ID: 31703842
    [Abstract] [Full Text] [Related]

  • 40. Platinum(IV) complex-based two-in-one polyprodrug for a combinatorial chemo-photodynamic therapy.
    Guo D, Xu S, Huang Y, Jiang H, Yasen W, Wang N, Su Y, Qian J, Li J, Zhang C, Zhu X.
    Biomaterials; 2018 Sep 15; 177():67-77. PubMed ID: 29885587
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.